Q3 EPS Estimate for Soleno Therapeutics Increased by Analyst

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share (EPS) estimate for Soleno Therapeutics to ($0.01), significantly improving from a prior estimate of ($0.62).
• Soleno Therapeutics reported earnings of ($0.09) per share in its last release, beating consensus estimates significantly, alongside revenue of $32.66 million for the quarter.
• The stock has a market cap of $3.55 billion and is currently rated as "Buy" by most brokerages, with an average price target of $114.30.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Investment analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Soleno Therapeutics in a report released on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.01) per share for the quarter, up from their previous forecast of ($0.62). HC Wainwright has a "Buy" rating and a $110.00 price objective on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q4 2025 earnings at $0.17 EPS, FY2025 earnings at ($0.78) EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.98 EPS and FY2026 earnings at $2.40 EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.44. The business had revenue of $32.66 million for the quarter, compared to the consensus estimate of $3.91 million.

Several other analysts have also issued reports on the company. Guggenheim increased their target price on Soleno Therapeutics from $97.00 to $106.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Wall Street Zen raised shares of Soleno Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. TD Cowen started coverage on shares of Soleno Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating and a $110.00 target price on the stock. Wells Fargo & Company started coverage on shares of Soleno Therapeutics in a report on Wednesday. They set an "overweight" rating and a $123.00 price target for the company. Finally, Oppenheimer increased their price target on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. According to MarketBeat, Soleno Therapeutics currently has an average rating of "Buy" and an average price target of $115.09.

Soleno Therapeutics Price Performance

NASDAQ:SLNO traded down $1.23 during trading hours on Wednesday, reaching $68.57. 1,150,393 shares of the company were exchanged, compared to its average volume of 1,650,533. The business has a 50 day moving average of $81.95 and a 200 day moving average of $69.82. Soleno Therapeutics has a 1-year low of $41.50 and a 1-year high of $90.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 15.13 and a quick ratio of 15.01. The company has a market capitalization of $3.64 billion, a P/E ratio of -16.56 and a beta of -2.56.

Institutional Investors Weigh In On Soleno Therapeutics

A number of large investors have recently bought and sold shares of SLNO. Nomura Holdings Inc. raised its holdings in shares of Soleno Therapeutics by 156.7% during the second quarter. Nomura Holdings Inc. now owns 3,644 shares of the company's stock valued at $305,000 after purchasing an additional 10,075 shares during the period. Castleark Management LLC acquired a new stake in shares of Soleno Therapeutics in the 2nd quarter valued at about $2,919,000. Headlands Technologies LLC bought a new stake in Soleno Therapeutics in the 2nd quarter valued at about $204,000. Tower Research Capital LLC TRC raised its stake in Soleno Therapeutics by 137.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,116 shares of the company's stock worth $261,000 after buying an additional 1,806 shares during the period. Finally, Exome Asset Management LLC boosted its holdings in Soleno Therapeutics by 28.4% in the second quarter. Exome Asset Management LLC now owns 41,641 shares of the company's stock worth $3,489,000 after acquiring an additional 9,200 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Patricia C. Hirano sold 3,830 shares of the business's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider directly owned 13,206 shares of the company's stock, valued at $1,092,928.56. The trade was a 22.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.40% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.